Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance.

Vicentini C, Cantù C, Antonello D, Simbolo M, Mafficini A, Luchini C, Rusev B, Porcaro AB, Iacovelli R, Fassan M, Corbo V, Brunelli M, Artibani W, Scarpa A, Lawlor RT.

Pathol Res Pract. 2018 Oct;214(10):1675-1680. doi: 10.1016/j.prp.2018.08.031. Epub 2018 Aug 29.

2.

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.

Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS, Visakorpi T.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T. Epub 2013 Oct 1.

3.

Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, Lange PH, Snyder LA, Srivastava S, Corey E, Vessella RL, Nelson PS, Üren A, Morrissey C.

Prostate. 2016 Jun;76(9):810-22. doi: 10.1002/pros.23171. Epub 2016 Mar 16.

4.

[TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].

Xiao L, Zhu XZ, Wang Y, Gong Y, Guo CC.

Zhonghua Bing Li Xue Za Zhi. 2011 Jun;40(6):392-6. Chinese.

PMID:
21914348
5.

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.

Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E.

Mod Pathol. 2010 Nov;23(11):1492-8. doi: 10.1038/modpathol.2010.149. Epub 2010 Aug 6.

6.

ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.

Powell K, Semaan L, Conley-LaComb MK, Asangani I, Wu YM, Ginsburg KB, Williams J, Squire JA, Maddipati KR, Cher ML, Chinni SR.

Clin Cancer Res. 2015 Jun 1;21(11):2569-79. doi: 10.1158/1078-0432.CCR-14-2352. Epub 2015 Mar 9.

7.

Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer.

Murphy SJ, Kosari F, Karnes RJ, Nasir A, Johnson SH, Gaitatzes AG, Smadbeck JB, Rangel LJ, Vasmatzis G, Cheville JC.

Cancer Res. 2017 Nov 15;77(22):6157-6167. doi: 10.1158/0008-5472.CAN-17-0529. Epub 2017 Nov 10.

8.
9.

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.

Neoplasia. 2006 Oct;8(10):885-8.

10.

Somatic alterations contributing to metastasis of a castration-resistant prostate cancer.

Nickerson ML, Im KM, Misner KJ, Tan W, Lou H, Gold B, Wells DW, Bravo HC, Fredrikson KM, Harkins TT, Milos P, Zbar B, Linehan WM, Yeager M, Andresson T, Dean M, Bova GS.

Hum Mutat. 2013 Sep;34(9):1231-41. doi: 10.1002/humu.22346. Epub 2013 Jun 3.

11.

A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.

Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M.

Cancer Genet. 2013 Jan-Feb;206(1-2):1-11. doi: 10.1016/j.cancergen.2012.12.004. Epub 2013 Jan 24.

12.

High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.

Smit FP, Salagierski M, Jannink S, Schalken JA.

BJU Int. 2013 May;111(5):836-42. doi: 10.1111/bju.12119.

13.

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.

Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA.

Mod Pathol. 2010 Apr;23(4):539-46. doi: 10.1038/modpathol.2009.193. Epub 2010 Jan 29.

14.

PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.

Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS, Joshua AM, Fleshner NE, Squire JA, Evans AJ.

Mod Pathol. 2013 Mar;26(3):435-47. doi: 10.1038/modpathol.2012.162. Epub 2012 Sep 28.

15.

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.

Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA.

Mod Pathol. 2008 Dec;21(12):1451-60. doi: 10.1038/modpathol.2008.96. Epub 2008 May 23.

16.

Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.

Hernández S, Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Salido M, Fumadó L, Serrano L, Cecchini L, Serrano S, Lloreta J.

Prostate. 2016 Jun;76(9):854-65. doi: 10.1002/pros.23176. Epub 2016 Mar 9.

PMID:
26959281
17.

ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.

Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, Osunkoya AO, MacLennan GT, Montironi R, Cheng L.

Mod Pathol. 2011 Aug;24(8):1120-7. doi: 10.1038/modpathol.2011.56. Epub 2011 Apr 15.

18.

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.

Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS; Transatlantic Prostate Group.

Oncogene. 2008 Jan 10;27(3):253-63. Epub 2007 Jul 16.

19.

TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.

Swanson TA, Krueger SA, Galoforo S, Thibodeau BJ, Martinez AA, Wilson GD, Marples B.

Prostate. 2011 Oct 1;71(14):1548-58. doi: 10.1002/pros.21371. Epub 2011 Mar 10.

PMID:
21394739
20.

TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.

Jiang H, Mao X, Huang X, Zhao J, Wang L, Xu J, Zhang H, Lu Y, Yu Y.

Tumour Biol. 2016 Sep;37(9):12397-12402. Epub 2016 Jun 20. Erratum in: Tumour Biol. 2016 Oct;37(10 ):14331.

PMID:
27320318

Supplemental Content

Support Center